期刊
FRONTIERS IN PUBLIC HEALTH
卷 8, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fpubh.2020.552028
关键词
epidemiology; human papillomavirus (HPV); HPV-related disease; molecular pathogenesis; cervicovaginal microbiome; natural history; intratypic molecular variant
资金
- Strategic Priority Research Program of the Chinese Academy of Sciences [XDB29030104]
- National Natural Science Fund [31870731, U1732109]
- Fundamental Research Funds for the Central Universities
- 100 Talents Programme of The Chinese Academy of Sciences
- Chinese Government Scholarship
- CAS-TWAS fellowship
- University of Science and Technology of China's Scholarship
- National Natural Science Foundation of China [81872110, 81272881]
- National Key Research and Development Program [2018YFC1003903]
- Anhui Provincial Key Research and Development Projects [1704a0802151]
HPV is the most common pathogen responsible for female cancers, with infections related to various diseases. The distribution of HPV infections and related diseases varies significantly depending on factors such as region and population.
Diagnosed in more than 90% of cervical cancers, the fourth deadliest cancer in women, human papillomavirus (HPV) is currently the most common pathogen responsible for female cancers. Moreover, HPV infection is associated with many other diseases, including cutaneous and anogenital warts, and genital and upper aerodigestive tract cancers. The incidence and prevalence of these pathologies vary considerably depending on factors including HPV genotype, regional conditions, the study population, and the anatomical site sampled. Recently, features of the cervicovaginal microbiota are found to be associated with the incidence of HPV-related diseases, presenting a novel approach to identify high-risk women through both blood and cervical samples. Overall, the HPV repartition data show that HPV infection and related diseases are more prevalent in developing countries. Moreover, the available (2-, 4-, and 9-valent) vaccines based on virus-like particles, despite their proven effectiveness and safety, present some limitations in terms of system development cost, transport cold chain, and oncogenic HPV variants. In addition, vaccination programs face some challenges, leading to a considerable burden of HPV infection and related diseases. Therefore, even though the new (9-valent) vaccine seems promising, next-generation vaccines as well as awareness programs associated with HPV vaccination and budget reinforcements for immunization are needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据